GLP-1 maintenance dosing for PCOS: what two years actually looks like

What did @itsmekelsc actually say?

The creator describes two years of weight maintenance on a GLP-1 medication, staying at roughly 10 milligrams and dosing every nine to ten days rather than the standard weekly schedule. She credits this approach with keeping her PCOS symptoms, including cycle irregularity and inflammation, under control. She's transparent that her endocrinologist guides her protocol and that recent bloodwork showed slightly elevated testosterone and low estrogen, which she describes as typical for PCOS.

She also pushes back on the idea that maintenance always means reducing your dose or stretching out injections, saying, "maintenance looks so different for everyone." She eats three meals a day, doesn't count calories, and aims for around 100 grams of protein. The overall tone is personal anecdote with a consistent disclaimer to talk to your doctor, which is more responsible than most GLP-1 content on TikTok.

Does the science back this up?

The off-label dosing interval is the most medically interesting part here, and there's actually some pharmacokinetic logic behind it. Most evidence supports weekly dosing, but individual variation in drug clearance is real.

GLP-1 receptor agonists like semaglutide have a half-life of approximately seven days, which is why weekly dosing is standard for products like Ozempic and Wegovy. Stretching to 10 days could theoretically allow trough levels to drop low enough for symptoms to return, which tracks with her observations. A 2022 pharmacokinetic review in Clinical Pharmacokinetics (Overgaard et al.) confirmed that semaglutide's steady-state levels drop significantly beyond seven days in some patients.

On the PCOS side, GLP-1 receptor agonists have shown genuine promise. A 2023 randomized trial published in Fertility and Sterility (Elkind-Hirsch et al.) found that GLP-1 therapy improved menstrual regularity and reduced androgen levels in women with PCOS and obesity. Her observation that longer dosing gaps trigger cycle disruption is biologically plausible given this mechanism.

What did they get wrong (or right)?

She gets credit for accuracy on the PCOS-GLP-1 connection. The science does support her experience. Where she's on shakier ground is implying that her specific dosing schedule, 10 mg every nine to ten days, is something others might replicate. It is not a validated protocol.

The 10 mg figure is also worth pausing on. This likely refers to tirzepatide (Mounjaro or Zepbound), which is dosed at 5, 7.5, 10, 12.5, and 15 mg. That's a meaningful detail she doesn't clarify, and 104,000 viewers guessing at which drug she's on is a real problem. Dose numbers mean nothing without knowing the medication.

Her bloodwork comment is actually a point in her favor. She's not ignoring the hormonal signal, she's reporting it. But casually noting "my testosterone is a little elevated" while simultaneously extending dosing intervals sends mixed messages. If her endocrinologist is recommending every 10 days and she's stretching to two weeks, that's not maintenance optimization, that's non-adherence with acknowledged consequences.

What should you actually know?

GLP-1 medications are not one-size-fits-all, and maintenance dosing genuinely varies by individual. That part of her message is sound. But the specifics she shares, dose numbers, injection intervals, symptom responses, are her data points from her body under her doctor's supervision. They should not be treated as a template.

PCOS is a real and under-treated condition, and GLP-1 receptor agonists are being studied seriously for it. A 2021 meta-analysis in Obesity Reviews (Liu et al.) found GLP-1 agonists significantly reduced BMI, fasting insulin, and testosterone in women with PCOS. The mechanism likely involves insulin sensitization and reduced ovarian androgen production, not a direct hormonal fix.

If you have PCOS and are considering or currently on a GLP-1, the takeaway from this video should be: work with an endocrinologist, track your symptoms, and get bloodwork done regularly. Do not self-adjust your dosing schedule based on someone else's maintenance routine.

Bottom line

This video is more responsible than average. The creator isn't selling anything, repeatedly defers to her doctor, and shares real clinical data including her bloodwork. The core message that maintenance is individualized and PCOS can affect your GLP-1 needs is supported by evidence. The risk is in the specifics: viewers may latch onto her dose number or injection interval without the clinical context that makes those numbers meaningful for her specifically.